Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …

Rationale: Paclitaxel resistance is a major concern when treating triple-negative breast
cancer (TNBC) patients. We aimed to identify candidates causing paclitaxel resistance and …

Developing treatment strategies for triple-negative breast cancer (TNBC) has become an
important clinical challenge. Currently, taxane-based chemotherapy is one of the standard …

Abstract Background/Aims: Triple negative breast cancer (TNBC) is a highly aggressive form
of cancer which lacks targeted therapy options. Thus, TNBC patients have poor outcomes …

Paclitaxel is a chemotherapeutic agent that acts as an inhibitor of cellular mitosis and has
been widely used in the treatment of triple‐negative breast cancer (TNBC). However …

Background: Chemotherapy is the main treatment for triple-negative breast cancer (TNBC),
which lack molecular markers for diagnosis and therapy. Cancer cells activate …

Triple-negative breast cancer (TNBC) is among the most notorious types of breast cancer,
the treatment of which does not give consistent results due to the absence of the three …

Triple-negative breast cancer (TNBC) is a particularly aggressive mammary neoplasia with a
high fatality rate, mainly because of the development of resistance to administered …

Background: Taxanes are frontline chemotherapeutic drugs for patients with triple-negative
breast cancer (TNBC); however, chemoresistance reduces their effectiveness. We …

Introduction Paclitaxel is a widely used drug in the treatment of patients with locally
advanced and metastatic breast cancer. However, only a small portion of patients have a …